Claim Your New User Special: Get your second month free ▶ Second Month Free

Serving leading biopharmaceutical companies globally:

McKesson
McKinsey
AstraZeneca
Express Scripts
Johnson and Johnson
Colorcon

Last Updated: May 28, 2022

CLINICAL TRIALS PROFILE FOR CERUBIDINE


✉ Email this page to a colleague

« Back to Dashboard

All Clinical Trials for Cerubidine

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00002590 ↗ Combination Chemotherapy in Treating Children With Lymphoma Completed National Cancer Institute (NCI) Phase 2 1994-07-01 RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. PURPOSE: Phase II trial to study the effectiveness of combination chemotherapy in treating children who have lymphoma.
NCT00002590 ↗ Combination Chemotherapy in Treating Children With Lymphoma Completed Children's Oncology Group Phase 2 1994-07-01 RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. PURPOSE: Phase II trial to study the effectiveness of combination chemotherapy in treating children who have lymphoma.
NCT00002798 ↗ Combination Chemotherapy With or Without Bone Marrow Transplantation in Treating Children With Acute Myelogenous Leukemia or Myelodysplastic Syndrome Completed National Cancer Institute (NCI) Phase 3 1996-08-01 Randomized phase III trial to compare the effectiveness of different chemotherapy regimens with or without bone marrow transplantation in treating children who have acute myelogenous leukemia or myelodysplastic syndrome. Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining chemotherapy with bone marrow transplantation may allow the doctor to give higher doses of chemotherapy drugs and kill more cancer cells. It is not yet known which treatment regimen is more effective for acute myelogenous leukemia or myelodysplastic syndrome
NCT00003190 ↗ Combination Chemotherapy With or Without Valspodar in Treating Patients With Previously Untreated Acute Myeloid Leukemia Completed National Cancer Institute (NCI) Phase 3 1998-01-01 Randomized phase III trial to compare the effectiveness of combination chemotherapy with or without PSC 833 followed by interleukin-2 or no further therapy in treating older patients who have acute myeloid leukemia. Some cancers become resistant to chemotherapy drugs. Combining PSC 833 with more than one chemotherapy drug may reduce resistance to the drugs and allow the cancer cells to be killed. Combining interleukin-2 with combination chemotherapy plus PSC 833 may kill more cancer cells.
NCT00003593 ↗ Chemotherapy in Treating Children With Down Syndrome and Myeloproliferative Disorder, Acute Myelogenous Leukemia, or Myelodysplastic Syndrome Completed National Cancer Institute (NCI) Phase 3 1999-06-01 RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. PURPOSE: Phase III trial to study the effectiveness of combination chemotherapy in treating children who have Down syndrome and myeloproliferative disorder, acute myelogenous leukemia, or myelodysplastic syndrome.
NCT00003593 ↗ Chemotherapy in Treating Children With Down Syndrome and Myeloproliferative Disorder, Acute Myelogenous Leukemia, or Myelodysplastic Syndrome Completed Children's Oncology Group Phase 3 1999-06-01 RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. PURPOSE: Phase III trial to study the effectiveness of combination chemotherapy in treating children who have Down syndrome and myeloproliferative disorder, acute myelogenous leukemia, or myelodysplastic syndrome.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Cerubidine

Condition Name

Condition Name for Cerubidine
Intervention Trials
Untreated Adult Acute Myeloid Leukemia 19
Acute Myeloid Leukemia 18
Leukemia 12
Acute Lymphoblastic Leukemia 10
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Cerubidine
Intervention Trials
Leukemia 64
Leukemia, Myeloid, Acute 36
Leukemia, Myeloid 33
Precursor Cell Lymphoblastic Leukemia-Lymphoma 30
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Cerubidine

Trials by Country

Trials by Country for Cerubidine
Location Trials
Canada 155
Australia 64
New Zealand 23
Puerto Rico 16
Switzerland 12
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Cerubidine
Location Trials
Illinois 42
North Carolina 41
California 38
New York 37
Maryland 36
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Cerubidine

Clinical Trial Phase

Clinical Trial Phase for Cerubidine
Clinical Trial Phase Trials
Phase 3 27
Phase 2/Phase 3 2
Phase 2 21
[disabled in preview] 16
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Cerubidine
Clinical Trial Phase Trials
Completed 34
Active, not recruiting 18
Recruiting 7
[disabled in preview] 6
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Cerubidine

Sponsor Name

Sponsor Name for Cerubidine
Sponsor Trials
National Cancer Institute (NCI) 53
Children's Oncology Group 20
Wake Forest University Health Sciences 3
[disabled in preview] 6
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Cerubidine
Sponsor Trials
NIH 53
Other 48
Industry 13
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

McKesson
Merck
McKinsey
Mallinckrodt
Medtronic
Dow

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.